Immunodiagnostic Systems Hldgs PLC Director/PDMR Shareholding (2753F)
July 11 2019 - 9:16AM
UK Regulatory
TIDMIDH
RNS Number : 2753F
Immunodiagnostic Systems Hldgs PLC
11 July 2019
Immunodiagnostic Systems Holdings PLC
Director/PDMR Dealing
11 July 2019
Immunodiagnostic Systems Holdings PLC ("IDS") a specialist
producer of manual and automated diagnostic testing kits and
instruments for the clinical and research markets, announces that
it has granted the following options to persons discharging
managerial responsibilities to acquire ordinary shares of 2p in the
capital of the Company under the Company's Co-Investment Executive
Option Scheme.
Position Date of Grant Number of Options Exercise Price
Paul Martin Finance Director 28 March 2017 30,000 GBP1.320
----------------- -------------- ------------------ ---------------
28 March 2017 9,000 GBP2.775
----------------- -------------- ------------------ ---------------
29 March 2018 6,000 GBP2.200
-------------- ------------------ ---------------
29 March 2018 6,300 GBP2.900
-------------- ------------------ ---------------
28 March 2019 6,750 GBP1.840
----------------- -------------- ------------------ ---------------
Jaap Stuut CEO 29 March 2018 7,500 GBP2.200
----------------- -------------- ------------------ ---------------
28 March 2019 7,500 GBP1.900
----------------- -------------- ------------------ ---------------
Nicola Mitton HR Director 29 March 2018 3,000 GBP2.200
----------------- -------------- ------------------ ---------------
Under this scheme, participants who purchase ordinary shares in
the Company ("Co-Investment Shares") are entitled to three share
options for each Co-Investment Share they purchase. The exercise
price for the options is set at the price the participant paid for
each Co-Investment Share.
The options are subject to the satisfaction of performance
conditions and vest after a period of 3 years. The Options are
exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
For further information:
Immunodiagnostic Systems Holdings Tel : +44 (0)191
plc 519 0660
Paul Martin, Group Finance Director
Peel Hunt LLP Tel : +44 (0)207
418 8900
James Steel
Oliver Jackson
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name 1. Paul Martin
2. Jaap Stuut
3. Nicola Mitton
------------------ -------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a. Position/ 1. Group Finance Director
status 2. Chief Executive Officer
3. HR Director
------------------ -------------------------------------------------------
a. Initial Initial
notification
/Amendment
------------------ -------------------------------------------------------
3. Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---------------------------------------------------------------------------
a. Name Immunodiagnostic Systems Holdings plc
------------------ -------------------------------------------------------
b. LEI 213800HZMYTD4NGF4L78
------------------ -------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
---------------------------------------------------------------------------
a. Description Options over ordinary shares of 2p each
of the Financial in Immunodiagnostic Systems Holdings plc
instrument,
Type of Ordinary shares
instrument GB00B01YZ052
Identification
code
------------------ -------------------------------------------------------
b. Nature of Grant of options
the transaction
------------------ -------------------------------------------------------
c. Price(s) Date of Grant Number Exercise
and volume(s) of Options Price
Paul Martin 28 March 30,000 GBP1.320
2017
-------------- ------------ ---------
28 March 9,000 GBP2.775
2017
-------------- ------------ ---------
29 March 6,000 GBP2.200
2018
-------------- ------------ ---------
29 March 6,300 GBP2.900
2018
-------------- ------------ ---------
28 March 6,750 GBP1.840
2019
-------------- ------------ ---------
Jaap Stuut 29 March 7,500 GBP2.200
2018
-------------- ------------ ---------
28 March 7,500 GBP1.900
2019
-------------- ------------ ---------
Nicola 29 March 3,000 GBP2.200
Mitton 2018
-------------- ------------ ---------
------------------ -------------------------------------------------------
d. Aggregated N/A
information
------------------ -------------------------------------------------------
e. Date of see table above in section c
the transaction
------------------ -------------------------------------------------------
f. Place of Outside trading venue - shares to be admitted
the transaction to AIM market of London Stock Exchange
plc on exercise of options
------------------ -------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBXGDRSBBBGCB
(END) Dow Jones Newswires
July 11, 2019 09:16 ET (13:16 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jul 2023 to Jul 2024